DOI: 10.6084/m9.figshare.26780521.v1
title: Supplementary materials: Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

description: <b>These are peer-reviewed supplementary materials for the article '</b><b>Efficacy of CARVYKTI in CARTITUDE-4 </b><b>versus other conventional treatment </b><b>regimens for lenalidomide-refractory </b><b>multiple myeloma using inverse probability </b><b>of treatment weighting</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S</b><b>1</b><b>:</b> Study characteristics of daratumumab clinical trials<b>Table S2:</b> Availability of prognostic factors in the daratumumab clinical trials<b>Table S3: </b>Multiple imputation of missing variables in CANDOR<b>Table S4: </b>Overview of baseline characteristics for cilta-cel (CARTITUDE-4) versus DVd (CASTOR) before and after adjustment with IPTW using ATT and ATC<b>Table S5: </b>Overview of baseline characteristics for cilta-cel (CARTITUDE-4) versus Vd (CASTOR) before and after adjustment with IPTW using ATT and ATC<b>Table S6: </b>Overview of baseline characteristics for cilta-cel (CARTITUDE-4) versus DKd (CANDOR) before and after adjustment with IPTW using ATT and ATC<b>Table S7: </b>Overview of baseline characteristics for cilta-cel (CARTITUDE-4) versus Kd (CANDOR) before and after adjustment with IPTW using ATT and ATC<b>Table S8: </b>Overview of baseline characteristics for cilta-cel (CARTITUDE-4) versus Pd (APOLLO) before and after adjustment with IPTW using ATT and ATC<b>Table S9: </b>ATT-adjusted HR with corresponding 95% CIs using categorization of ≥3 months as the time-dependent covariate in a Cox regression model<b>Figure S1: </b>RMST differences for cilta-cel versus comparators<b>Figure S2</b>: Comparative efficacy of cilta-cel versus comparators across sensitivity analyses for ORR<b>Figure S3</b>: Comparative efficacy of cilta-cel versus comparators across sensitivity analyses for ≥VGPR<b>Figure S4</b>: Comparative efficacy of cilta-cel versus comparators across sensitivity analyses for ≥CR<b>Figure S5</b>: Comparative efficacy of cilta-cel versus comparators across sensitivity analyses for PFS<b>References</b><b>Aim:</b> The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory multiple myeloma (RRMM) patients who have received one to three prior line(s) of therapy (LOT[s]) including an immunomodulatory agent and a proteasome inhibitor, and are refractory to lenalidomide. These analyses estimate the relative efficacy between cilta-cel and other common treatment regimens, for which no direct comparative evidence is available. <b>Materials & methods:</b> Patient data were available from the CARTITUDE-4, CASTOR, CANDOR and APOLLO RCTs. Imbalances between cohorts on key patient characteristics were adjusted for using inverse probability of treatment weighting (IPTW). Relative efficacies were estimated with response rate ratios (RRs) and 95% confidence intervals (CIs) for overall response rate (ORR), very good partial response or better rate (≥VGPR) and complete response or better rate (≥CR), and with hazard ratios (HRs) and 95% CIs for progression-free survival (PFS). Sensitivity analyses using different analytical methods and additional covariates were explored. <b>Results:</b> Key characteristics were well balanced across cohorts after IPTW. Cilta-cel showed statistically significant benefit in PFS (HRs: 0.11–0.51), ≥VGPR (RRs: 1.51–5.13) and ≥CR (RRs: 2.90–35.24) versus all comparators, and statistically significant improvements in ORR over most comparator regimens (RRs: 1.22–1.90). Results were consistent across sensitivity analyses. <b>Conclusion: </b>Cilta-cel demonstrated benefit over other common treatment regimens, highlighting its potential to become a new standard of care option for lenalidomide-refractory RRMM patients with one to three prior LOT(s). These comparisons help to demonstrate the improved efficacy of cilta-cel in countries where the standard of care may differ from DPd/PVd.